Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Goodwill (2020 - 2025)

Historic Goodwill for Cytek Biosciences (CTKB) over the last 6 years, with Q3 2025 value amounting to $16.7 million.

  • Cytek Biosciences' Goodwill rose 318.24% to $16.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.7 million, marking a year-over-year increase of 318.24%. This contributed to the annual value of $16.7 million for FY2024, which is 296.61% up from last year.
  • As of Q3 2025, Cytek Biosciences' Goodwill stood at $16.7 million, which was up 318.24% from $16.7 million recorded in Q2 2025.
  • Cytek Biosciences' Goodwill's 5-year high stood at $19.1 million during Q1 2023, with a 5-year trough of $476000.0 in Q2 2021.
  • Its 5-year average for Goodwill is $13.2 million, with a median of $16.2 million in 2023.
  • As far as peak fluctuations go, Cytek Biosciences' Goodwill surged by 203109.24% in 2021, and later tumbled by 1546.26% in 2024.
  • Quarter analysis of 5 years shows Cytek Biosciences' Goodwill stood at $10.1 million in 2021, then changed by 0.0% to $10.1 million in 2022, then soared by 59.53% to $16.2 million in 2023, then increased by 2.97% to $16.7 million in 2024, then grew by 0.21% to $16.7 million in 2025.
  • Its Goodwill was $16.7 million in Q3 2025, compared to $16.7 million in Q2 2025 and $16.7 million in Q1 2025.